Descovy (emtricitabine / tenofovir alafenamide)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Descovy (emtricitabine / tenofovir alafenamide)

Manufacturer Gilead Sciences Pty Ltd
Disease HIV / AIDS
Indication HIV-1 infection
Mode of Action Antiviral
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 200 mg / 10 mg, 200 mg / 25 mg

Who is emtricitabine / tenofovir alafenamide for?

Descovy (emtricitabine / tenofovir alafenamide) is indicated for the treatment of individuals infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is used in adults and adolescents aged over 12 years and who weigh at least 35 kg [1].

Recommended dose

Complete information about Descovy (emtricitabine / tenofovir alafenamide) dosage and administration can be found here [2][3][4].
The FDA standard dosage is:
  • 1 tablet 200 mg / 25 mg daily
The EMA and TGA standard dosage is
  • 200 mg / 10 mg once daily if taken together with atazanavir with ritonavir or cobicistat, darunavir with ritonavir or cobicistat, or lopinavir with ritonavir
  • 200 mg / 25 mg once daily if taken with dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine, or raltegravir [2][4]
Consult your treating doctor for personalised dosing.

What is emtricitabine / tenofovir alafenamide and how does it work?

Descovy (emtricitabine / tenofovir alafenamide) is an antiviral medicine used to treat adults and adolescents aged over 12 years and who weigh at least 35 kg infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS) [1].
Each tablet of Descovy (emtricitabine / tenofovir alafenamide) contains 200 mg of emtricitabine and either 10 or 25 mg of tenofovir alafenamide. Inside the body tenofovir alafenamide is converted into the active substance tenofovir. Tenofovir and emtricitabine block the activity of the enzyme made by the virus to reproduce itself in the cells it has infected. It thus keeps the amount of HIV in the blood at a low level.
Descovy (emtricitabine / tenofovir alafenamide) does not cure HIV infection or AIDS, but it can prevent damages to the immune system and the development of infections and diseases associated with AIDS.

What is emtricitabine / tenofovir alafenamide's approval status?

Descovy (emtricitabine / tenofovir alafenamide) was approved among others by:
  • FDA on April 4, 2016 [5]
  • EMA (EU) on April 21, 2016 [1]
  • TGA (AUS) on November 22, 2016 [4]
For the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older in combination with other antiretroviral agents.  
The approvals were based on several studies that compared emtricitabine /tenofovir alafenamide (F/TAF)-based regimens (i.e. regimens including Descovy) with emtricitabine / tenofovir disoproxil (F/TDF)-based regimens (e.g. regimens including Viread), and demonstrated the ability of Descovy (F/TAF) to produce the same drug levels as F/TDF regimens at a dose of tenofovir of less than one tenth [5][2].
Clinical studies on treatment-naive patients (GS-US-292-0104 and GS-US-292-0111) have shown that F/TAF-based regimens produce similar results, in terms of viral load, to F/TDF-based regimens. The number of individuals with a viral load (HIV-1 RNA) of less than 50 copies per mL of plasma after 48 weeks was 92 % for those on F/TAF and 90 % for those on F/TDF, while being 84 % vs 80 % after 144 weeks [2].
In study GS-US-311-1089, the efficacy and safety of switching from F/TDF to Descovy (F/TAF) while maintaining the third antiretroviral agent were evaluated in patients with a stable low viral load for at least 6 months (HIV-1 RNA < 50 copies/mL). The percentage of individuals with a maintained low viral load was similar in the tested cohorts and in both around 90 % [2].
Moreover, F/TAF-based regimens were associated with smaller reductions in bones mineral density (BMD) and a lower impact on renal safety parameters as compared to F/FDF-based regimens [2].
The most common side effect is nausea (feeling sick). Other common side effects include diarrhoea and headache. [1].
[1] EMA. Human Medicines: Descovy (emtricitabine / tenofovir alafenamide), 01/06/2016, cited on 01/08/2017.
[2] Summary of Product Characteristics [EMA]: Descovy (emtricitabine / tenofovir alafenamide), Gilead Sciences International Ltd., Apr. 2016.
[3] Summary of Product Characteristics [FDA]: Descovy (emtricitabine / tenofovir alafenamide), Gilead Sciences Inc., Apr. 2017
[4] Summary of Product Characteristics [TGA]: Descovy (emtricitabine / tenofovir alafenamide), Gilead Sciences Pty Ltd, May 2017.
[5] FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy. 04/04/2016

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.